The University of Miami Adapt (UAdapt) Trial

Prostate Cancer Clinical Trial

Official title:

A Phase 2 Risk Adapted Parallel Randomized Trial of MRI-Guided Lattice Stereotactic Focal Radiotherapy of the Prostate With or Without Ultra-Short Term Androgen Deprivation Therapy-The Miami UAdapt Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06111313
• Other study ID #: 20230097
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2024
• Est. completion date: September 1, 2032

Study information

• Verified date: May 2024
• Source: University of Miami
• Contact: Benjamin Spieler, MD
• Phone: 305-243-4229
• Email: bxs737[@]med.miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Miami UAdapt Trial is a risk-adapted parallel randomized study using single high-dose radiotherapy (SDRT) to treat favorable and unfavorable risk prostate cancer patients. The primary objective of the study is to determine the proportion of patients with Biochemical and/or Clinical Disease Failure 1 year after completion of radiotherapy (RT).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: September 1, 2032
• Est. primary completion date: September 1, 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 35 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Biopsy confirmed adenocarcinoma of the prostate (including intraductal adenocarcinoma, excluding small cell carcinoma).

2. T1-T3 disease based on digital rectal exam (DRE), informed by mpMRI. Prostate MRI may aid in the staging evaluation by verifying organ-confined status6,7. The ability to distinguish between organ-confined tumors (=T2c) and those that extend beyond the prostate (=T3a) is an important component of treatment decision making.

3. Patients with T3 disease based on DRE, mpMRI, Gleason 8-10, or a PSA of >15 ng/mL, should undergo a negative metastatic workup prior to signing of consent. A questionable bone scan is acceptable if additional imaging studies; eg, plain x-rays, CT, MRI, prostate specific membrane antigen (PSMA) positron emission tomography (PET)/CT do not confirm for metastasis.

4. No evidence of metastasis by clinical criteria or available radiographic tests (N0M0 by clinical or imaging criteria).

5. Gleason score 6-10.

6. Prostate specific antigen (PSA) =100 ng/mL within (=) 3 months of signing of consent. If PSA was above 100 ng/mL and drops to =100 ng/mL with antibiotics, this is acceptable for enrollment.

7. Suspicious peripheral zone or central gland lesion(s) on mpMRI.

1. Peripheral zone: Distinct lesion on dynamic contrast enhanced (DCE)-MRI with early enhancement and later washout (Note: contrast not required for enrollment), and/or distinct lesion on the apparent diffusion coefficient (ADC) map (Value <1000).

2. Central gland: A suspicious central gland lesion on mpMRI must have a distinct lesion on the ADC map (Value <1000).

8. No previous pelvic radiotherapy.

9. No previous history of radical/total prostatectomy (suprapubic prostatectomy is acceptable).

10. No concurrent, active malignancy, other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for =5 years, then the patient is eligible.

11. Ability to understand and the willingness to sign a written informed consent document.

12. Zubrod performance status =2. Karnofsky or Eastern Cooperative Oncology Group (ECOG) performance status may be used to estimate Zubrod.

13. Age =35 and =85 years at signing of consent.

14. Serum testosterone is within 40% of normal assay limits (eg, x=0.4*lower assay limit and x=0.4*upper assay limit + upper assay limit), taken within (=) 3 months of signing of consent.

15. For patients in HypoLEAD cohort, post-LEAD RT androgen deprivation therapy, including use of secondary agents (eg, abiraterone), is at the discretion of the treating physician but must be declared as none, short-term or long-term prior to enrollment. Note that this ADT regimen differs from the uSTADT regimen. If antiandrogen therapy (eg, bicalutamide) or ADT (LHRH agonist or antagonist injection) is planned, the

following restrictions apply:

1. Anti-androgen therapy and ADT must be started after 3-week post-LEAD RT gradient biopsy.

2. Anti-androgen therapy and ADT are recommended to be started prior to or concurrent with start of moderately hypofractionated RT course and must be started before the end of the hypofractionated RT course.

3. The total length planned must be = 30 months.

16. Patient unable to receive iodine or gadolinium contrast due to allergy or poor renal function are still eligible for enrollment.

Exclusion Criteria:

1. Prior pelvic radiotherapy.

2. Prior androgen ablation therapy.

3. Prior or planned radical prostate surgery.

4. Clinical, radiographic, or pathologic evidence of nodal or distant metastatic disease with the following specifications: PSMA-PET or Fluciclovine PET: Patients with subclinical (<1.5 cm) pelvic lymph nodes that are suspicious on such PET scans will be ineligible for FTLEAD, however will still be eligible for HypoLEAD. In the latter case the treating physician may boost such nodes to a higher dose.

5. Concurrent, active malignancy, other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for > 5 years, then the patient is eligible.

6. Zubrod status >2.

7. Pretreatment PSA >100 ng/ml or Gleason score <6. If PSA was above 100 ng/mL and drops to =100 ng/mL with antibiotics, this is acceptable for enrollment.

8. Thyroxine (T4) disease.

9. Patients with impaired decision-making capacity who lack the ability to understand and voluntarily sign a written informed consent document.

10. Patients unable to tolerate diagnostic MRI acquisition. Note: inability to tolerate contrast agents is not exclusionary.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• FTLEAD
In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.

Drug:
• Ultra-Short-Term Androgen Deprivation Therapy with Relugolix
Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.

Radiation:
• HypoLEAD
In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.

Drug:
• ADT Standard of Care
Participants will receive ADT as per standard of care (SOC).

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	Varian Medical Systems

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Patients with Biochemical Disease Failure	Biochemical Disease Failure will be determined by the proportion of patients with biochemical disease failure.	Up to 14 Months
Primary	Proportion of Patients with Clinical Disease Failure	Clinical Disease Failure will be determined by the proportion of patients with clinical disease failure. Clinical disease failure will include the proportion of patients with biopsy finding of treatment failure.	Up to 14 Months
Secondary	Proportion of Patients with Biochemical Disease Failure	Biochemical Disease Failure will be determined by the proportion of patients with biochemical disease failure.	Up to 2.5 years
Secondary	Proportion of Patients with Clinical Disease Failure	Clinical Disease Failure will be determined by the proportion of patients with clinical disease failure. Clinical disease failure will include the proportion of patients with biopsy finding of treatment failure.	Up to 2.5 years
Secondary	Proportion of Patients with Pathology-determined complete response (PathCR)	Pathology-determined complete response (PathCR) is defined as proportion of patients with negative prostate biopsy findings on both template plus image-guided habitat biopsy.	Up to 14 Months
Secondary	Proportion of Patients with Pathology-determined complete response (PathCR)	Pathology-determined complete response (PathCR) is defined as proportion of patients with negative prostate biopsy findings on both template plus image-guided habitat biopsy.	Up to 2.5 year
Secondary	Incidence of Failure rate (FR)	Failure rate is defined as the cumulative incidence of biopsy finding of treatment failure (BxTF), biochemical failure (BF), or clinical failure (CF), or combined (BxTF plus BF plus CF), where combined failure refers to documented evidence of BxTF, BF, and CF occurring within 6 months of each other with the earlier date used, or death related to prostate cancer without prior evidence of failure, whichever is earlier, from study enrollment allowing for competing risk as needed.	Up to 2.5 years
Secondary	Number of Treatment Related Acute toxicity	Acute toxicity is defined as grade 2+ and grade 3+ treatment-related acute genitourinary (GU)/gastrointestinal (GI) toxicity occurring during treatment and within 3 months of completing treatment. The severity of the reactions to treatment will be scored according to the criteria outline in CTCAE version 5.0.	Up to 3 months
Secondary	Number of Treatment Related Late toxicity	Late toxicity is defined as grade 2+ and grade 3+ treatment-related GU/GI toxicity occurring more than 3 months after completing study treatment. The severity of the reactions to treatment will be scored according to the criteria outline in CTCAE version 5.0.	Up to 8 Years